استراتژی‌های طراحی واکسن پیشرفته برای توکسوپلاسموزیس: تجزیه و تحلیل محاسباتی پروتئین روپتری 13(ROP13) توکسوپلاسما گوندی

References

1. Rostami A, Riahi SM, Gamble HR, Fakhri Y, Nourollahpour Shiadeh M, Danesh M, et al. Global prevalence of latent toxoplasmosis in pregnant women: A systematic review and meta-analysis. Clin Microbiol Infect. 2020; 26(6):673-83. [DOI:10.1016/j.cmi.2020.01.008] [PMID]
2. Abbasali Z, Pirestani M, Dalimi A, Badri M, Fasihi-Ramandi M. Anti-parasitic activity of a chimeric peptide Cecropin A (2- 8)-Melittin (6- 9)(CM11) against tachyzoites of Toxoplasma gondii and the BALB/c mouse model of acute toxoplasmosis. Mol Biochem Parasitol. 2023; 255:111578. [DOI:10.1016/j.molbiopara.2023.111578] [PMID]
3. Rojas-Barón L, Tana-Hernandez L, Nguele Ampama MH, Sanchéz R, Gärtner U, Wagenlehner FME,et al. Adverse impact of acute Toxoplasma gondii infection on human spermatozoa. FEBS J. 2025; 292(17):4720-36. [PMID]
4. Sanchez SG, Besteiro S. The pathogenicity and virulence of Toxoplasma gondii. Virulence. 2021; 12(1):3095-114. [DOI:10.1080/21505594.2021.2012346] [PMID]
5. Haghbin M, Maani S, Bagherzadeh MA, Bazmjoo A, Shakeri H, Taghipour A, et al. Latent Toxoplasmosis among Breast Cancer Patients in Jahrom, South of Iran. Int J Breast Cancer. 2023; 2023:4792260. [DOI:10.1155/2023/4792260] [PMID]
6. Dubey JP. The history of Toxoplasma gondii the first 100 years. J Eukaryot Microbiol. 2008; 55(6):467-75. [DOI:10.1111/j.1550-7408.2008.00345.x] [PMID]
7. Wang ZD, Liu HH, Ma ZX, Ma HY, Li ZY, Yang ZB, et al. Toxoplasma gondii infection in immunocompromised patients: A systematic review and meta-analysis. Front Microbiol. 2017; 8:389. [DOI:10.3389/fmicb.2017.00389] [PMID]
8. Mose JM, Kagira JM, Kamau DM, Maina NW, Ngotho M, Karanja SM, et al. A review on the present advances on studies of toxoplasmosis in eastern Africa. Biomed Res Int. 2020; 2020:7135268. [DOI:10.1155/2020/7135268] [PMID]
9. Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis. Semin Immunopathol. 2012; 34(6):793-813. [DOI:10.1007/s00281-012-0339-3] [PMID]
10. Abdoli A, Olfatifar M, Eslahi AV, Moghadamizad Z, Samimi R, Habibi MA, et al. A systematic review and meta-analysis of protozoan parasite infections among patients with mental health disorders: An overlooked phenomenon. Gut Pathog. 2024;16(1):7. [DOI:10.1186/s13099-024-00602-2] [PMID]
11. Gharavi MJ, Jalali S, Khademvatan S, Heydari S. Detection of IgM and IgG anti-Toxoplasma antibodies in renal transplant recipients using ELFA, ELISA and ISAGA methods: Comparison of pre-and post-transplantation status. Ann Trop Med Parasitol. 2011; 105(5):367-71. [DOI:10.1179/1364859411Y.0000000022] [PMID]
12. Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical observations. Int J Parasitol. 2009; 39(8):895-901. [DOI:10.1016/j.ijpara.2009.02.004] [PMID]
13. Tenter AM. Toxoplasma gondii in animals used for human consumption. Mem Inst Oswaldo Cruz. 2009; 104(2):364-9.[DOI:10.1590/S0074-02762009000200033] [PMID]
14. Hajj RE, Tawk L, Itani S, Hamie M, Ezzeddine J, El Sabban M, et al. Toxoplasmosis: Current and emerging parasite druggable targets. Microorganisms. 2021; 9(12):2531. [DOI:10.3390/microorganisms9122531] [PMID]
15. Antczak M, Dzitko K, Dugoska H. Human toxoplasmosis Searching for novel chemotherapeutics. Biomed Pharmacother. 2016; 82:677-84. [DOI:10.1016/j.biopha.2016.05.041] [PMID]
16. Pagheh AS, Sarvi S, Sharif M, Rezaei F, Ahmadpour E, Dodangeh S, et al. Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: A systematic review. Comp Immunol Microbiol Infect Dis. 2020; 69:101414. [DOI:10.1016/j.cimid.2020.101414] [PMID]
17. Zhang NZ, Chen J, Wang M, Petersen E, Zhu XQ. Vaccines against Toxoplasma gondii: New developments and perspectives. Expert Rev Vaccines. 2013; 12(11):1287-99. [DOI:10.1586/14760584.2013.844652] [PMID]
18. Rezaei F, Sarvi S, Sharif M, Hejazi SH, Pagheh AS, Aghayan SA, et al. A systematic review of Toxoplasma gondii antigens to find the best vaccine candidates for immunization. Microb Pathog. 2019; 126:172-84. [DOI:10.1016/j.micpath.2018.11.003] [PMID]
19. Kazi A, Chuah C, Majeed ABA, Leow CH, Lim BH, Leow CY. Current progress of immunoinformatics approach harnessed for cellular-and antibody-dependent vaccine design. Pathog Glob Health. 2018; 112(3):123-31. [DOI:10.1080/20477724.2018.1446773] [PMID]
20. Dlugonska H. Toxoplasma rhoptries: Unique secretory organelles and source of promising vaccine proteins for immunoprevention of toxoplasmosis. J Biomed Biotechnol. 2008; 2008:632424. [DOI:10.1155/2008/632424] [PMID]
21. Pagheh AS, Daryani A, Alizadeh P, Hassannia H, Rodrigues Oliveira SM, Kazemi T, et al. Protective effect of a DNA vaccine cocktail encoding ROP13 and GRA14 with Alum nano-adjuvant against Toxoplasma gondii infection in mice. Int J Biochem Cell Biol. 2021; 132:105920. [DOI:10.1016/j.biocel.2021.105920] [PMID]
22. Turetzky JM, Chu DK, Hajagos BE, Bradley PJ. Processing and secretion of ROP13: A unique Toxoplasma effector protein. Int J Parasitol. 2010; 40(9):1037-44. [DOI:10.1016/j.ijpara.2010.02.014] [PMID]
23. Wang PY, Yuan ZG, Petersen E, Li J, Zhang XX, Li XZ, et al. Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice. Clin Vaccine Immunol. 2012; 19(12):1916-20. [DOI:10.1128/CVI.00397-12] [PMID]
24. Kang HJ, Lee SH, Kim MJ, Chu KB, Lee DH, Chopra M, et al. Influenza virus-like particles presenting both Toxoplasma gondii ROP4 and ROP13 Enhance Protection against T. gondii infection. Pharmaceutics. 2019; 11(7):342. [DOI:10.3390/pharmaceutics11070342] [PMID]
25. Zhou J, Wang L, Zhou A, Lu G, Li Q, Wang Z, et al. Bioinformatics analysis and expression of a novel protein ROP48 in Toxoplasma gondii. Acta Parasitol. 2016; 61(2):319-28. [DOI:10.1515/ap-2016-0042] [PMID]
26. Romano P, Giugno R, Pulvirenti A. Tools and collaborative environments for bioinformatics research. Brief Bioinform. 2011; 12(6):549-61. [DOI:10.1093/bib/bbr055] [PMID]
27. National Center for Biotechnology Information (NCBI). amino acid sequence of ROP13. National Center for Biotechnology Information; 2025. [Link]
28. The Expasy ProtParam tool. Vaud: SIB Swiss Institute of Bioinformatics; 2025. [Link]
29. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, et al. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The Proteomics Protocols Handbook. Springer Protocols Handbooks. New Jersey: Humana Press. [DOI:10.1385/1-59259-890-0:571]
30. No Auther. The online tools NetPhos 3.1 [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
31. No Auther. CSS-Palm. [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
32. TMHMM-2.0. Kongens Lyngby: Technical University of Denmark; 2025. [Link]
33. PSORT II Prediction [Internet]. 1999 [Updated 24 November 1999]. Available from: [Link]
34. The secondary structure of ROP13 was predicted using the Garnier-Osguthorpe-Robson (GOR) method through the online server. 2025.
35. Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol. 1996; 266:540-53. [DOI:10.1016/S0076-6879(96)66034-0] [PMID]
36. SWISS-MODEL. SWISSMODEL program [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
37. Guex N, Peitsch MC, Schwede T. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. Electrophoresis. 2009; 30(S1):S162--73. [DOI:10.1002/elps.200900140] [PMID]
38. UCLA-DOE LAB — SAVES v6.1. PROCHECK tool [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
39. Foroutan M, Karimipour-Saryazdi A, Ghaffari AD, Majidiani H, Arzani Birgani A, Karimzadeh-Soureshjani E, et al. In Silico Analysis and Characterization of the Immunogenicity of Toxoplasma gondii Rhoptry Protein 18. Bioinform Biol Insights. 2025; 19:11779322251315924. [DOI:10.1177/11779322251315924] [PMID]
40. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996; 8(4):477-86. [DOI:10.1007/BF00228148] [PMID]
41. Computational Resources for Drug Discovery. ABCpred server. [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
42. Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 2006; 65(1):40-8. [DOI:10.1002/prot.21078] [PMID]
43. Computational Resources for Drug Discovery. Bcepred tool. 2025.
44. Saha S, Raghava GPS. BcePred: prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. Paper presented at: International Conference on Artificial Immune Systems. September 13-16, 2004; Catania, Sicily, Italy. [Link]
45. IEDB Analysis Resource. IEDB tool [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
46. IEDB Analysis Resource. ElliPro [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
47. Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: A new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 2008; 9:514. [PMID]
48. The Immune Epitope Database (IEDB). Assess the half maximal inhibitory concentration (IC50) of peptides derived from ROP13 that exhibit af finity to both major histocompatibility complex (MHC) class I and class II molecules [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
49. IEDB Analysis Resource. MHC-I Binding Predictions [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
50. IEDB Analysis Resource. MHC class II [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
51. Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 2008; 4(4):e1000048. [DOI:10.1371/journal.pcbi.1000048] [PMID]
52. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 2010; 11:568. [PMID]
53. tools. CTLpred tool. [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
54. Bhasin M, Raghava GP. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine. 2004; 22(23-24):3195-204. [DOI:10.1016/j.vaccine.2004.02.005] [PMID]
55. Scratch Protein Predictor. ANTI‌GENpro [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
56. Magnan CN, Zeller M, Kayala MA, Vigil A, Randall A, Felgner PL, et al. High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics. 2010; 26(23):2936-43. [DOI:10.1093/bioinformatics/btq551] [PMID]
57. The Edward Jenner Institute for Vaccine Research. VaxiJen v. 2.0. [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
58. Doytchinova IA, Flower DR. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007; 8:4. [PMID]
59. Allergenic profile of ROP13 was predicted using the AlgPred [Internet]. 2025 [Updated 26 November 2025].
60. Saha S, Raghava GP. AlgPred: Prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 2006; 34(Web Server issue):W202-9. [PMID]
61. Magnan CN, Randall A, Baldi P. SOLpro: Accurate sequence-based prediction of protein solubility. Bioinformatics. 2009; 25(17):2200-7. [DOI:1093/bioinformatics/btp386] [PMID]
62. C-IMMSIM. C-ImmSim was employed to simulate the virtual immunological response triggered by TgROP13 [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
63. Kur J, Holec-Gasior L, Hiszczyńska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev Vaccines. 2009; 8(6):791-808. [DOI:10.1586/erv.09.27] [PMID]
64. Dodangeh S, Fasihi-Ramandi M, Daryani A, Valadan R, Sarvi S. In silico analysis and expression of a novel chimeric antigen as a vaccine candidate against Toxoplasma gondii. Microb Pathog. 2019; 132:275-81. [DOI:10.1016/j.micpath.2019.05.013] [PMID]
65. Berzofsky JA. Immunogenicity and antigen structure. Fundam Immunol. 1993; 235–82. [Link]
66. El Hajj H, Demey E, Poncet J, Lebrun M, Wu B, Galéotti N, et al. The ROP2 family of Toxoplasma gondii rhoptry proteins: proteomic and genomic characterization and molecular modeling. Proteomics. 2006; 6(21):5773-84. [DOI:10.1002/pmic.200600187]
67. Walsh C. Posttranslational modification of proteins: Expanding nature’s inventory. York City: W. H. Freeman and Company; 2006. [Link]
68. DTU Health Tech. Number of predicted TMHs. DTU Health Tech; 2025. [Link]
69. Yada RY, Jackman RL, Nakai S. Secondary structure prediction and determination of proteins: A review. Int J Pept Protein Res. 1988; 31(1):98–108. [DOI:10.1111/j.1399-3011.1988.tb00011.x]
70. Predicted secondary structure by the GOR IV online service. [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
71. Wang Y, Wang G, Cai J, Yin H. Review on the identification and role of Toxoplasma gondii antigenic epitopes. Parasitol Res. 2016; 115(2):459-68. [DOI:10.1007/s00436-015-4824-1] [PMID]
72. Zaki L, Ghaffarifar F, Sharifi Z, Horton J, Sadraei J. Effect of Imiquimod on Tachyzoites of Toxoplasma gondii and Infected Macrophages in vitro and in BALB/c Mice. Front Cell Infect Microbiol. 2020; 10:387. [DOI:10.3389/fcimb.2020.00387] [PMID]
73. Zaki L, Ghaffarifar F, Sharifi Z, Horton J, Sadraei J. Toxoplasma gondii: Preventive and therapeutic effects of morphine and evaluation of treatment parameters of tachyzoites and infected macrophages in vitro and in a murine model. EXCLI J. 2020; 19:514-27. [PMID]
74. Sayles PC, Gibson GW, Johnson LL. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun. 2000; 68(3):1026-33. [DOI:10.1128/IAI.68.3.1026-1033.2000] [PMID]
75. El-Kady IM. T-cell immunity in human chronic toxoplasmosis. J Egypt Soc Parasitol. 2011; 41(1):17-28. [PMID]
76. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. In- terferon-gamma: The major mediator of resistance against Toxoplasma gondii. Science. 1988; 240(4851):516-8. [DOI:10.1126/science.3128869] [PMID]